Express Pharma

Moderna maintains vaccine sales view as demand from low-income nations eases

The unchanged forecast came despite Moderna's $1.74 billion deal last week with the US government for 66 million doses of a vaccine updated for Omicron subvariants

1 245

Moderna yesterday retained its full-year sales outlook for COVID-19 shot at $21 billion due to decreasing orders from low- and middle-income countries through the COVAX international vaccine-sharing programme.

The unchanged forecast came despite Moderna’s $1.74 billion deal last week with the US government for 66 million doses of a vaccine updated for Omicron subvariants.

“It’s because of COVAX. As you remember, we have a partnership with COVAX to supply product to low-income countries. COVAX does not want the doses that they have ordered,” Stephane Bancel, Chief Executive, Moderna, told Reuters.

Market expectations of an increase in vaccine sales have been dropping, with analysts divided on the sustainability of that dizzying growth beyond 2022 on doubts over demand for booster doses.

Moderna reported $4.5 billion in sales of its shot in the second-quarter ended 30th June. Three analysts polled by Refinitiv had expected quarterly sales of $3.16 billion.

Edits by EP News Bureau

- Advertisement -